← feed

Is NCT03916601 results overdue?

Yes — results are overdue. Primary completion was 2018-03-22; the FDAAA-801 reporting deadline (2019-03-22) passed 2694 days ago and no results are posted on ClinicalTrials.gov.

Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus

NCT IDNCT03916601 ↗
SponsorSanofi (INDUSTRY)
Public issuerSanofi — SNY (CIK 0001121404) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-03-22 (ACTUAL)
Reporting deadline2019-03-22 (completion + 365d)
Days overdue2694
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 580350888dde9bb9… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03916601. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →